MGRX — Mangoceuticals Income Statement
0.000.00%
Last trade - 00:00- $23.20m
- $23.12m
- $0.62m
Annual income statement for Mangoceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0.009 | 0.731 | 0.616 |
| Cost of Revenue | ||||
| Gross Profit | 0 | 0.005 | 0.431 | 0.38 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Total Operating Expenses | 0.018 | 2 | 9.95 | 9.31 |
| Operating Profit | -0.018 | -1.99 | -9.22 | -8.69 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.018 | -2 | -9.21 | -8.71 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.018 | -2 | -9.21 | -8.71 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.018 | -2 | -9.21 | -8.71 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.018 | -2 | -9.21 | -8.71 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.015 | -1.73 | -8.58 | -4.4 |
| Dividends per Share |